Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2025 02:00 ET | Source: Persica Pharmaceuticals

Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain

Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain The PP353 clinical trial met the...
November 19, 2024 02:00 ET | Source: Persica Pharmaceuticals

Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025

Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025 Persica is developing PP353, a potentially curative, opioid-sparing...
March 07, 2024 03:00 ET | Source: Persica Pharmaceuticals

Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain

Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held,...
March 24, 2022 04:00 ET | Source: Persica Pharmaceuticals

Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons

Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons London, UK, 24 March 2022 – Persica Pharmaceuticals Ltd, a clinical stage...
August 19, 2021 02:00 ET | Source: Persica Pharmaceuticals

Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain

Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain Novel approach applicable to 20% of all CLBP populationsFirst...